Bristol-Myers Squibb Co. will pay BioNTech SE as much as $11.1 billion to license a next-generation cancer drug, as competition intensifies in an area of oncology that seeks to harness the immune system to attack tumors. Bloomberg’s Damian Garde reports. (Source: Bloomberg)
www.bloomberg.com
#BristolMyers #Pay #Billion #License #Cancer #Drug
Bristol-Myers to Pay $11 Billion to License Cancer Drug
